You are here

Article Text

Article menu
Download PDFPDF
Therapeutics
Amlodipine or lisinopril was not better than chlorthalidone in lowering CHD risk in hypertension

https://doi.org/10.1136/ebm.8.4.105

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    (2002) JAMA 288, 2981. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).. ;. :. –97..
    OpenUrlCrossRefPubMedWeb of Science

    
 
 QUESTION: In predominately older patients with hypertension and ≥1 other coronary heart disease (CHD) risk factor, is amlodipine or lisinopril better than chlorthalidone in lowering the risk for CHD or other cardiovascular disease (CVD) events?

    Design

    Randomised (allocation concealed*), blinded {patients, clinicians, data collectors, outcome assessors, and steering committee}†,* controlled trial with mean 4.9 years of follow up (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial [ALLHAT]).

    Setting

    623 centres in the US, Canada, Puerto Rico, and the US Virgin Islands.

    Patients

    33 357 patients ≥55 years of age (mean age 67 y, 53% men) who had stage 1 or stage 2 hypertension and ≥1 additional risk factor for CHD. The risk factors were myocardial infarction (MI) or stroke in the previous 6 months, left ventricular hypertrophy, type 2 diabetes, smoking, high density lipoprotein cholesterol <0.91 mmol/l, or other atherosclerotic CVD. Patients with a history of heart failure (HF) or known left ventricular ejection fraction <35% were excluded. Follow up was 97%; all randomised …

    View Full Text

    Footnotes

    • Sources of funding: National Heart, Lung, and Blood Institute and Pfizer.

    • For correspondence: Dr J T Wright, Case Western Reserve University, Cleveland, OH, USA. jxw20{at}po.cwru.edu; Dr B R Davis, University of Texas-Houston Health Science Center, Houston, TX, USA. bdavis{at}sph.uth.tmc.edu

    • Abstracts and commentary also appear in ACP Journal Club.

    • ↵* See glossary.

    • ↵† Information provided by author.